Comments (continue).

JAV/Hospira (neutral or buy)

JAV/Hospira Dyloject™ (diclofenac sodium injection).

Javelin completed randomized, four-way cross-over phase I clinical study comparing the pharmacokinetic, bioequivalence and safety of Dyloject™ to Voltarol® when administered intravenously and intramuscularly. Dyloject™ was found to be bioequivalent to Voltarol® regardless of the method of administration and was safe and well tolerated. At all dosage levels tested, Dyloject™ provided statistically significant post operative pain relief through 6 hours (p <0.05) and was safe and well-tolerated by patients. Injectable diclofenac is already marketed in United Kingdom & Scotland with indications of post operative pain and anti-inflammatory.

Disclosure: HSP pps now is around $55 with market cap $9.21B. This big pharma has enough broad drug portfolio so approval of Dyloject™ will add not so much. However it will positive news for HSP, so may be share price will add $2-3. No position in HSP.